Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14481390 | 0.89 | CYP3A4 (0.34) | AAK1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL12324243 | 0.82 | CPB2 (0.39) | GPR88AAK1CPB2L3MBTL1CTSK | |
| SCHEMBL13568010 | 0.81 | AAK1 (0.34) | GPR88AAK1L3MBTL1CTSKCTSS | |
| SCHEMBL5026306 | 0.80 | CYSLTR2 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5026303 | 0.80 | CYSLTR2 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL23689304 | 0.78 | TRPA1 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL14481752 | 0.78 | TRPA1 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL27450106 | 0.78 | TRPA1 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL10233950 | 0.77 | CYP3A4 (0.35) | AAK1CPB2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31491215 | 0.77 | MMP13 (0.41) | AAK1L3MBTL1CTSKCTSSCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| WO-2011115065-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | 第一三共株式会社 (JP) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | GPR88 4264/4885AAK1 3789/4885CPB2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.